Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sebastian Kloss

Showing results (1-10 of 11) with videos related to

Pageof 2
Sort By:
International Journal of Cardiology. Heart & Vasculature|May 22, 2019
Comparative effectiveness of rivaroxaban versus a vitamin K antagonist in patients with renal impairment treated for non-valvular atrial fibrillation in Germany - A retrospective cohort studyHendrik Bonnemeier, Maria Huelsebeck, Sebastian Kloss
Pharmaceutical Statistics|June 14, 2016
Safety data from randomized controlled trials: applying models for recurrent eventsJohannes Hengelbrock, Johanna Gillhaus, Sebastian Kloss, et al.
Pharmacoepidemiology and Drug Safety|February 26, 2011
Linkage of mother-baby pairs in the German Pharmacoepidemiological Research DatabaseEdeltraut Garbe, Marc Suling, Sebastian Kloss, et al.
Zeitschrift Fur Evidenz, Fortbildung Und Qualitat Im Gesundheitswesen|November 28, 2018
[Estimating the incidence of venous thromboembolism (VTE) using various types of routine data of the German healthcare system]Christoph Ohlmeier, Friedhelm Leverkus, Sebastian Kloss, et al.
International Journal of Cardiology|March 4, 2024
Comparative effectiveness of factor Xa non-vitamin K antagonist oral anticoagulants versus phenprocoumon in patients with non-valvular atrial fibrillationReinhold Kreutz, Sebastian Kloss, Dirk Enders, et al.
BMJ Open|September 29, 2016
Early real-world evidence of persistence on oral anticoagulants for stroke prevention in non-valvular atrial fibrillation: a cohort study in UK primary careMichelle E Johnson, Cinira Lefèvre, Shuk-Li Collings, et al.
Pharmacoepidemiology and Drug Safety|November 9, 2022
High-dimensional propensity scores for empirical covariate selection in secondary database studies: Planning, implementation, and reportingJeremy A Rassen, Patrick Blin, Sebastian Kloss, et al.
GMS Infectious Diseases|January 24, 2019
Treatment of MRSA pneumonia: Clinical and economic comparison of linezolid vs. vancomycin - a retrospective analysis of medical charts and re-imbursement data of real-life patient populationsMichael H Wilke, Karsten Becker, Sebastian Kloss, et al.
Drug Discovery Today|January 17, 2018
The positive impacts of Real-World Data on the challenges facing the evolution of biopharmaJohn Wise, Angeli Möller, David Christie, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 14, 2025
Real-World Outcomes of Elacestrant in ER+, HER2-, ESR1-Mutant Metastatic Breast CancerHope S Rugo, Virginia Kaklamani, Heather McArthur, et al.
Pageof 2

Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
International Journal of Cardiology. Heart & Vasculature|May 22, 2019
Comparative effectiveness of rivaroxaban versus a vitamin K antagonist in patients with renal impairment treated for non-valvular atrial fibrillation in Germany - A retrospective cohort studyHendrik Bonnemeier, Maria Huelsebeck, Sebastian Kloss
Pharmaceutical Statistics|June 14, 2016
Safety data from randomized controlled trials: applying models for recurrent eventsJohannes Hengelbrock, Johanna Gillhaus, Sebastian Kloss, et al.
Pharmacoepidemiology and Drug Safety|February 26, 2011
Linkage of mother-baby pairs in the German Pharmacoepidemiological Research DatabaseEdeltraut Garbe, Marc Suling, Sebastian Kloss, et al.
Zeitschrift Fur Evidenz, Fortbildung Und Qualitat Im Gesundheitswesen|November 28, 2018
[Estimating the incidence of venous thromboembolism (VTE) using various types of routine data of the German healthcare system]Christoph Ohlmeier, Friedhelm Leverkus, Sebastian Kloss, et al.
International Journal of Cardiology|March 4, 2024
Comparative effectiveness of factor Xa non-vitamin K antagonist oral anticoagulants versus phenprocoumon in patients with non-valvular atrial fibrillationReinhold Kreutz, Sebastian Kloss, Dirk Enders, et al.
BMJ Open|September 29, 2016
Early real-world evidence of persistence on oral anticoagulants for stroke prevention in non-valvular atrial fibrillation: a cohort study in UK primary careMichelle E Johnson, Cinira Lefèvre, Shuk-Li Collings, et al.
Pharmacoepidemiology and Drug Safety|November 9, 2022
High-dimensional propensity scores for empirical covariate selection in secondary database studies: Planning, implementation, and reportingJeremy A Rassen, Patrick Blin, Sebastian Kloss, et al.
GMS Infectious Diseases|January 24, 2019
Treatment of MRSA pneumonia: Clinical and economic comparison of linezolid vs. vancomycin - a retrospective analysis of medical charts and re-imbursement data of real-life patient populationsMichael H Wilke, Karsten Becker, Sebastian Kloss, et al.
Drug Discovery Today|January 17, 2018
The positive impacts of Real-World Data on the challenges facing the evolution of biopharmaJohn Wise, Angeli Möller, David Christie, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 14, 2025
Real-World Outcomes of Elacestrant in ER+, HER2-, ESR1-Mutant Metastatic Breast CancerHope S Rugo, Virginia Kaklamani, Heather McArthur, et al.
Pageof 2